VRT
Vertex Pharmaceuticals Incorporated DR
Stock
Stock
ISIN: AR0468655268
Ticker: VRTX
AR0468655268
VRTX
Price
Price
CHART BY
Frequently asked questions
What is Vertex Pharmaceuticals Incorporated DR's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Vertex Pharmaceuticals Incorporated DR is 0.00. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Vertex Pharmaceuticals Incorporated DR?
Vertex Pharmaceuticals Incorporated DR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1,646,218.22. EPS indicates the company's profitability on a per-share basis.
What is Vertex Pharmaceuticals Incorporated DR's revenue over the trailing twelve months?
Over the trailing twelve months, Vertex Pharmaceuticals Incorporated DR reported a revenue of $13.35T.
What is the EBITDA for Vertex Pharmaceuticals Incorporated DR?
Vertex Pharmaceuticals Incorporated DR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $5.43T. EBITDA measures the company's overall financial performance.
What is the free cash flow of Vertex Pharmaceuticals Incorporated DR?
Vertex Pharmaceuticals Incorporated DR has a free cash flow of $3.75T. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Vertex Pharmaceuticals Incorporated DR have, and what sector and industry does it belong to?
Vertex Pharmaceuticals Incorporated DR employs approximately 6,100 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- EPS (TTM)
- $1,646,218.22
- P/E ratio (TTM)
- 0.00
- Revenue (TTM)
- $13.35T
- EBITDA (TTM)
- $5.43T
- Free Cashflow (TTM)
- $3.75T
Pricing
- 52W span
- $4.797$4.973
Information
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
- Employees
- 6,100
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- AR0468655268
- Primary Ticker
- VRTX
Fundamentals & EOD data from FactSet